# Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain

> **NCT00410787** · PHASE3 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 68 (actual)

## Conditions studied

- Analgesics, Opioid
- Pain

## Interventions

- **DRUG:** OROS hydromorphone HCI (slow release)

## Key facts

- **NCT ID:** NCT00410787
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2002-04
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2010-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410787, "Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00410787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*